

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,971	04/20/2005	Young-Hyeon Kwag	55198.3	5808
27128 7590 10/12/2007 BLACKWELL SANDERS LLP 720 OLIVE STREET			EXAMINER	
			MARX, IRENE	
SUITE 2400	ITE 2400 . LOUIS, MO 63101		ART UNIT	PAPER NUMBER
51. 20015, WK	0 03 101		1651	
			MAIL DATE	DELIVERY MODE
			10/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Summany	10/531,971	KWAG ET AL.			
Office Action Summary	Examiner	Art Unit			
	Irene Marx	1651			
The MAILING DATE of this communication app Period for Reply	pears on the cover sneet v	vitn the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN 136(a). In no event, however, may a will apply and will expire SIX (6) MC e. cause the application to become A	ICATION.  reply be timely filed  INTHS from the mailing date of this communication.  INTHS (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 6/25	<u>5/07</u> .				
,					
•	,—				
closed in accordance with the practice under	Ex parte Quayle, 1935 C.	D. 11, 453 O.G. 213.			
Disposition of Claims					
4) ⊠ Claim(s) <u>1 and 2</u> is/are pending in the applicate 4a) Of the above claim(s) <u>2</u> is/are withdrawn from 5) □ Claim(s) <u>is/are allowed.</u> 6) ⊠ Claim(s) <u>is/are rejected.</u> 7) □ Claim(s) <u>is/are objected to.</u> 8) □ Claim(s) <u>are subject to restriction and/or is/are object.</u>	rom consideration.				
Application Papers	•				
9) The specification is objected to by the Examine					
10)☐ The drawing(s) filed on is/are: a)☐ acc					
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat* See the attached detailed Office action for a list	nts have been received.  Its have been received in ority documents have been au (PCT Rule 17.2(a)).	Application No en received in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)	Paper N 5)  Notice o	v Summary (PTO-413) o(s)/Mail Date f Informal Patent Application			
Paper No(s)/Mail Date	6) [_] Other: _	·			

Application/Control Number: 10/531,971

Art Unit: 1651

#### DETAILED ACTION

The application should be reviewed for errors.

To facilitate processing of papers at the U.S. Patent and Trademark Office, it is recommended that the Application Serial Number be inserted on every page of claims and/or of amendments filed.

Applicant's election with traverse of Group I on 6/25/07 is acknowledged. The traversal appears to be on the ground(s) that Group I and Group II are closely related and have the common utility of selecting a mutant strain of KCCM 10340 to enhance growth activity and that there is no serious burden requiring separate searches.

However this is not found persuasive because applicant has not pointed out a specific error in the restriction requirement. In addition, burden lies not only in the search of U.S. patents, but in the search for literature and foreign patents and examination of the claim language and specification for compliance with the statutes concerning new matter, distinctness and scope of enablement.

Clearly different searches and issues are involved with each group.

For these reasons, the restriction requirement is deemed proper and is adhered to. The restriction requirement is hereby made FINAL.

### Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 1 is rejected under 35 U.S.C. 101 because this claim reads on the organism per se which is found in nature and thus, is unpatentable to applicant. Consequently, the claim does not embody patentable subject matter as defined in 35 USC 101. See, e.g., American Wood v. Fiber Disintegrating Co., 90 U.S. 566 (1974); American Fruit Growers v. Brogdex Co., 283 U.S. 1 (1931); Funk Brothers Seed. Co. v. Kalo Innoculant Co.., 33 U.S. 127 (1948); Diamond v. Chakrabarty, 206 U.S.P.Q. 193 (1980).

It is suggested that applicant use the language "a biologically pure culture" in connection with the strain to identify a product that is not found in nature and to indicate the hand of man.

Application/Control Number: 10/531,971

Art Unit: 1651

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is confusing in that the meaning of "which can rapidly overcome growth-standing phase on early culture" is not ascertainable. These are not terms of the art.

# Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 1 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The invention appears to employ a novel strain of *Corynebacterium ammoniagenes* to obtain a specific product. The written description of that strain and the method of isolating is insufficiently reproducible. Therefore, a deposit for patent purposes is required. The specification discloses at page 4 that the strain was deposited at KCCM under Budapest Treaty conditions on November 21, 2002.

For compliance with the rule, it must be averred that deposited material has been accepted for deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purpose of Patent Procedure (e.g. see 961 OG 21, 1977) and that all restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent. MPEP 2403.

Additionally, the deposit must be referred to in the body of the specification and be identified by deposit (accession) number, date of deposit, name and address of the depository and the complete taxonomic description.

Application/Control Number: 10/531,971

Art Unit: 1651

U.S. Patent No. 6,821,768 is cited as of interest. However, the instant strain distinguishes over the closest prior art strain disclosed in the reference in that the presently claimed strain *Corynebacterium ammoniagenes* CJXSP 0201 (Accession Number: KCCM 10448) produces a greater amount of 5'-xanthylic acid under the same process conditions than its parent, reference strain *Corynebacterium ammoniagenes* CJXPK001 (Accession Number: KCCM 10340). See, e.g., Specification, Examples.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (571) 272-0919. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Irene Marx
Primary Examiner
Art Unit 1651